Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Thalidomide: 40 years on
Autore:
Diggle, GE;
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 9, volume: 55, anno: 2001,
pagine: 627 - 631
SICI:
1368-5031(200111)55:9<627:T4YO>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Diggle, GE 97 Bennetts Way, Croydon CR0 8AG, Surrey, England 97 Bennetts Way Croydon Surrey England CR0 8AG Surrey, England
Citazione:
G.E. Diggle, "Thalidomide: 40 years on", INT J CL PR, 55(9), 2001, pp. 627-631

Abstract

Thalidomide was marketed in the late-1950s as a sedative and tranquilliserof exceptionally low general toxicity, but in 1961 it was implicated separately by Lenz and MacBride as the cause of the epidemic of congenital malformations that had been puzzling the world for some years. It is a very potent teratogen in humans, but in few other mammalian species; damage to the embryo is produced, at specific stages of gestation, but the mechanism of embryopathic action is still not understood. Following the withdrawal of the drug worldwide, it was consigned to the history of medical tragedies. In 1965, however, Sheskin discovered that it was effective in treating erythema nodosum leprosum, a distressing complication of leprosy. As the drug is neither an antibiotic nor an analgesic, its action was assumed to be immunosuppressive. In Brazil the drug was used widely with few regulatory controls, since when more than 100 cases of congenital malformation have appeared. Sheskin's discovery led to the experimental use of thalidomide in many other indications thought to possess some immunological component. In some cases,e.g. Behcet's syndrome, graft-versus-host disease and aphthous ulceration in HIV-positive patients, the drug has been shown to possess some efficacy. And! there is some evidence that it inhibits the replication of one of theimmunodeficiency viruses. The AIDS community in the US has exerted much pressure on the FDA to allow the drug on to the market, although the use of apotent immunosuppressive drug of unknown mechanism in an immunodeficiency condition raises further questions. Thalidomide is not always beneficial; its use is associated with an increased mortality in epidermal necrolysis. In 1991, D'Amato confirmed it possessed antiangiogenic properties and this led to further trials in malignant conditions. Results were mixed, but thosein multiple myeloma gave some grounds for optimism. In 1998, the FDA announced its extraordinary decision to grant marketing approval for thalidomide.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:26:50